Literature DB >> 12636164

Lung deposition and pharmacokinetics of cyclosporine after aerosolization in lung transplant patients.

Gilbert J Burkart1, Gerald C Smaldone, Michael A Eldon, Raman Venkataramanan, James Dauber, Adriana Zeevi, Kenneth McCurry, Teresa P McKaveney, Timothy E Corcoran, Bartley P Griffith, Aldo T Iacono.   

Abstract

PURPOSE: Aerosolized cyclosporine (aCsA) has proven to be an effective therapy for refractory acute and chronic rejection in lung transplant (LTx) patients. The objective of this study is to evaluate the lung deposition and systemic absorption of aCsA after aerosolized cyclosporine administration in LTx patients in the immediate postoperative period.
METHOD: Cyclosporine (CsA) was administered intravenously (1.0 mg/kg) to eight LTx patients, and multiple blood samples were collected over 24 h. At least 24 h later, aCsA (300 mg in propylene glycol) was administered to the same patients using nebulization and multiple blood samples were obtained again. Five patients had an additional inhalational gamma scintigraphy study with aCsA and 99MTc-labeled albumin to measure drug deposition.
RESULTS: Peak blood concentrations of CsA after aerosol administration ranged from 119-402 ng/ml, and concentrations at 24 h ranged from 9-48 ng/ml. The rate of decline in drug concentration in blood in the apparent elimination phase was notably slower after administration of aCsA than after IV infusion. Terminal disposition half life (t 1/2 lambda(z)) values ranged from 4.1-9.9 h (mean 6.5 h) following IV administration and from 23.1 to 65.2 h (mean 40.7 h) following pulmonary administration, suggesting that drug absorption occurred throughout the 24-h sampling period following pulmonary administration. Deconvolution analysis indicated biphasic absorption of CsA from the lung in all patients, characterized by rapid initial absorption (absorption half-life 0.73 +/- 0.38 h) over the first 4 to 6 h followed by slower, sustained absorption throughout the remainder of the sampling period (absorption half-life 16.2 +/- 13.2 h). The absolute bioavailability of CsA after aerosol administration ranged from 5.4-11.2% (mean 8.2%) of the dose placed in the nebulizer. The total dose delivered to the lung estimated from scintigraphy ranged from 17.8-39.3 mg, and was in approximate agreement with the amount of drug absorbed, estimated using deconvolution. Essentially all drug deposited in the lungs was systemically absorbed.
CONCLUSIONS: This study documents that cyclosporine can be effectively delivered by aerosolization to the lung of transplant patients in the early postoperative period. Part of the cyclosporine deposited in the lung is absorbed rapidly into systemic circulation and a portion is absorbed slowly but completely over a prolonged period.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12636164     DOI: 10.1023/a:1022275222207

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  10 in total

1.  Treatment of refractory acute allograft rejection with aerosolized cyclosporine in lung transplant recipients.

Authors:  R J Keenan; A Iacono; J H Dauber; A Zeevi; S A Yousem; N P Ohori; G J Burckart; A Kawai; G C Smaldone; B P Griffith
Journal:  J Thorac Cardiovasc Surg       Date:  1997-02       Impact factor: 5.209

2.  Treatment of presumed and proven acute rejection following six months of lung transplant survival.

Authors:  S Kesten; A Maidenberg; T Winton; J Maurer
Journal:  Am J Respir Crit Care Med       Date:  1995-10       Impact factor: 21.405

Review 3.  Management of lung transplant rejection.

Authors:  E P Trulock
Journal:  Chest       Date:  1993-05       Impact factor: 9.410

4.  Dose-related reversal of acute lung rejection by aerosolized cyclosporine.

Authors:  A T Iacono; G C Smaldone; R J Keenan; P Diot; J H Dauber; A Zeevi; G J Burckart; B P Griffith
Journal:  Am J Respir Crit Care Med       Date:  1997-05       Impact factor: 21.405

5.  Pharmacokinetics, pharmacodynamics, and safety of inhaled cyclosporin A (ADI628) after single and repeated administration in healthy male and female subjects and asthmatic patients.

Authors:  S Rohatagi; F Calic; N Harding; M L Ozoux; J P Bouriot; S Kirkesseli; L DeLeij; B K Jensen
Journal:  J Clin Pharmacol       Date:  2000-11       Impact factor: 3.126

Review 6.  Clinical pharmacokinetics of cyclosporin.

Authors:  R J Ptachcinski; R Venkataramanan; G J Burckart
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

Review 7.  Airway obstruction and bronchiolitis obliterans after lung transplantation.

Authors:  I Paradis; S Yousem; B Griffith
Journal:  Clin Chest Med       Date:  1993-12       Impact factor: 2.878

8.  Delivery and distribution of aerosolized cyclosporine in lung allograft recipients.

Authors:  T G O'Riordan; A Iacono; R J Keenan; S R Duncan; G J Burckart; B P Griffith; G C Smaldone
Journal:  Am J Respir Crit Care Med       Date:  1995-02       Impact factor: 21.405

9.  Acute rejection of lung allografts with various immunosuppressive protocols.

Authors:  B P Griffith; R L Hardesty; J M Armitage; R L Kormos; G C Marrone; S Duncan; I Paradis; J H Dauber; S A Yousem; P Williams
Journal:  Ann Thorac Surg       Date:  1992-11       Impact factor: 4.330

10.  Aerosolized cyclosporine in lung recipients with refractory chronic rejection.

Authors:  A T Iacono; R J Keenan; S R Duncan; G C Smaldone; J H Dauber; I L Paradis; N P Ohori; W F Grgurich; G J Burckart; A Zeevi; E Delgado; T G O'Riordan; M M Zendarsky; S A Yousem; B P Griffith
Journal:  Am J Respir Crit Care Med       Date:  1996-04       Impact factor: 21.405

  10 in total
  5 in total

Review 1.  The Evolution of Lung Transplant Immunosuppression.

Authors:  Steven Ivulich; Glen Westall; Michael Dooley; Gregory Snell
Journal:  Drugs       Date:  2018-07       Impact factor: 9.546

2.  Characterization of a cyclosporine solid dispersion for inhalation.

Authors:  Gerrit S Zijlstra; Michiel Rijkeboer; Dirk Jan van Drooge; Marc Sutter; Wim Jiskoot; Marco van de Weert; Wouter L J Hinrichs; Henderik W Frijlink
Journal:  AAPS J       Date:  2007-06-15       Impact factor: 4.009

3.  Lung deposition and pharmacokinetics of nebulized cyclosporine in lung transplant patients.

Authors:  T E Corcoran; R Niven; W Verret; S Dilly; B A Johnson
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2013-05-13       Impact factor: 2.849

Review 4.  Review: immunosuppression for the lung transplant patient.

Authors:  Sakhee Kotecha; Steven Ivulich; Gregory Snell
Journal:  J Thorac Dis       Date:  2021-11       Impact factor: 2.895

5.  Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried cyclosporine A multifunctional particles for dry powder inhalation aerosol delivery.

Authors:  Xiao Wu; Weifen Zhang; Don Hayes; Heidi M Mansour
Journal:  Int J Nanomedicine       Date:  2013-03-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.